Emerging biotherapies for Sjögren's syndrome. - Wikidata - wikimedia - TriplyDB

Emerging biotherapies for Sjögren's syndrome.

Emerging biotherapies for Sjögren's syndrome.

http://www.wikidata.org/entity/Q37729176

about

Allogenic banking of dental pulp stem cells for innovative therapeutics

P2860

Q26795542-B424D81B-ED53-49FD-9F94-74F369FCA752

P2860

Emerging biotherapies for Sjögren's syndrome.

http://www.wikidata.org/entity/Q37729176

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on June 2010

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Emerging biotherapies for Sjögren's syndrome.

@en

Emerging biotherapies for Sjögren's syndrome.

@nl

type

label

Emerging biotherapies for Sjögren's syndrome.

@en

Emerging biotherapies for Sjögren's syndrome.

@nl

prefLabel

Emerging biotherapies for Sjögren's syndrome.

@en

Emerging biotherapies for Sjögren's syndrome.

@nl

P1433

Q37729176-52B35C79-EB5B-4937-8F8A-CA9D7CBD6371

P1476

Q37729176-A22DE924-343D-456A-9D64-EF3A9EFA7E62

P2093

Q37729176-E4F47461-D9DB-4C73-9D17-45709F4F7C0F

P2860

Q37729176-0019B414-F97F-45D2-B163-3BEBFE07405A

Q37729176-01343791-6167-4CBE-AB19-E374CB34F66F

Q37729176-019BC9CA-FAB6-4EC0-BAD7-07BF04F09600

Q37729176-02A89FC9-530B-4284-BAA2-187517AF6F1F

Q37729176-0A63CD76-9CB8-4677-88F5-AFEAD12CFB56

Q37729176-0FAD07BA-FE24-42A1-AED3-2A431B56B92F

Q37729176-23567BB7-2D84-4F3F-BE79-D0E1ECBF6268

Q37729176-25969581-D95A-42CA-803D-2010FEF46BAF

Q37729176-25DED5AD-075D-4D53-B482-C5766899461E

Q37729176-2805EED5-5803-4FB1-B84C-A80DB8F61490

P304

Q37729176-8C2315A0-8918-4602-A8C8-BCD0BC47E53B

P31

Q37729176-A2D8A7B8-8B8D-4BEC-A6B5-30CBE7989074

P356

Q37729176-252A3D23-57FC-4499-8025-62E7D845E0BF

P407

Q37729176-E7FC5850-F512-4C15-85F0-D1104F005356

P433

Q37729176-385ADDCA-C7F9-4F30-8D95-D5BD6859D354

P478

Q37729176-95A64CF7-7D69-492B-AF1B-C3C60A7240BC

P50

Q37729176-3ED431DA-95C4-43FC-B82B-6046ED9589D1

Q37729176-8A2175F0-FAA2-4419-A9D1-65938606CA8E

Q37729176-EB16BF47-F844-4F76-8149-A170498AA6EB

P577

Q37729176-D1723EAC-7E38-4481-8E2E-04F3EA86A2BA

P698

Q37729176-75B19BD5-E9C3-43AA-854C-DB3E9228998A

P356

14728211003702392

P1433

Expert Opinion on Emerging Drugs

P1476

Emerging biotherapies for Sjögren's syndrome.

@en

P2093

Gabriel J Tobón

http://www.w3.org/2001/XMLSchema#string

P2860

BAFF, APRIL, TWE-PRIL: Who's who?

BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth

Resistance to rituximab therapy and local BAFF overexpression in Sjögren's syndrome-related myoepithelial sialadenitis and low-grade parotid B-cell lymphoma

Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator

Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjögren's syndrome.

Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned?

Sjögren's syndrome: current therapies remain inadequate for a common disease.

Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjögren's syndrome

Loss of TACI causes fatal lymphoproliferation and autoimmunity, establishing TACI as an inhibitory BLyS receptor.

Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis.

P304

269-282

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14728211003702392

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

15

http://www.w3.org/2001/XMLSchema#string

P50

Jacques-Olivier Pers

P577

2010-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20384543

http://www.w3.org/2001/XMLSchema#string